Thursday

2nd Feb 2023

Opinion

Von der Leyen's Pfizer texts - why transparency isn't all good

  • Ursula von der Leyen has a track record of suffering similar technological mishaps before - for instance, Blackberry phones she used as Germany's defence minister were also conveniently wiped out (Photo: Helena Malikova)
Listen to article

The president of the European Commission, Ursula von der Leyen, is under fire for having lost her text messages with the CEO of Pfizer, Albert Bourla. The charges are not entirely fair – and acting on them risks doing more harm than good.

The EU's ombudsman, Emily O'Reilly, said that the commission was guilty of "maladministration" when it failed to publicise the texts following a journalist's request.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Now, a momentum is building in the European Parliament to hold the commission accountable. "When giant vaccine deals are conducted via text messages, of course it is important for those providing oversight to be able see them," Sophie int'Veld, an influential Dutch MEP, argued.

While transparency is generally desirable in public life, there can also be too much of it. And, in fact, the commission's procurement of vaccines against Covid-19 is a case in point – notwithstanding the current brouhaha over 'Delete-gate'.

To be sure, von der Leyen herself has a track record of suffering similar technological mishaps before. The content of Blackberry phones that she used as Germany's defence minister, containing communications over lucrative government contracts, were also conveniently wiped out ("by negligence") ahead of a Bundestag inquiry.

Yet, there are good reasons to accord her significant leeway in this particular instance.

After all, the main problem afflicting the EU's approach to vaccine procurement, particularly in the autumn and winter months of 2020 was not the commission's excessive and non-transparent coziness with Big Pharma - but rather its risk aversion in face of possible scrutiny from member states, which had delegated it the task of purchasing vaccines for the entire EU.

The commission's early mistake was to do everything by the book, in order to insulate itself from any prospective criticism.

Hence the decision to diversify the vaccine portfolio to include not only Johnson & Johnson and Astra Zeneca, but also the failed Sanofi – instead of aggressively locking in, early on, a sufficient number of Pfizer and Moderna vaccines which were visibly superior.

Only in November of 2020 did the commission place a firm order for 200 million Pfizer doses, with an option for 100 million more, as well as 80 million doses from Moderna, with an option for another 80 million to be delivered at a later date.

The commission went out of its way to negotiate prices that were below those paid by other countries, such as the UK or Israel, preempting any accusations of extravagance.

What may have seemed prudent, however, was inadequate to the challenge posed by the pandemic.

The broader social and economic benefits of getting shots in people's arms exceeded any conceivable cost by one or two orders of magnitude. Protecting people and resuming normal life sooner rather than later was enormously valuable, too.

In short, this was the moment for the commission – and for policymakers across the developed world – to simply ignore the costs and go bold. Doing so, furthermore, would not have compromised the availability of vaccines for other, poorer countries – quite the contrary. The more generous initial bidders are, the easier it becomes for pharmaceutical companies to scale up and build additional capacity.

If anything, Von der Leyen should be applauded for changing the course in the spring of 2021, when the commission faced criticisms (including by myself) in the wake of its altercations with Astra Zeneca, whose deliveries were slipping behind the expected timeline.

In May of 2021, the commission thus announced a new contract with Pfizer to deliver as many as 1.8 billion doses to the EU, at higher price than before (€19.5 compared to €12 and €15.5 for earlier contracts).

The European public and EU governments are perfectly capable of judging for themselves whether the commission did a good job overall – and whether the additional expense was worth it. The amounts ordered (and delivered), the costs, and other contractual terms are all public information.

Deeply misguided

And legal formalities aside, the idea that all communication between the commission's officials and Pfizer should be also revealed to the public is deeply misguided.

For one, this was far from an instance of conventional public procurement, in which public authorities mechanically pick the objectively best bid, based on previously announced criteria. There are only a handful of companies in the world producing adequate vaccines against Covid-19 and their overall supply was long constrained.

It is possible, even probable, that the commission was not in the best position to act in a forward-looking, entrepreneurial manner to incentivise additional supply – particularly compared against the nimble ways in which British and Israeli governments operated – but it should not be penalised for having tried to do so, albeit late.

The corollary of the unfettered transparency that some MEPs are calling for is turning every negotiation, previously conducted in private, into a public relations exercise. It suggests that in future crises, public officials should always double down on their risk aversion and their commitment to process above all else – lest their text messages or in-person communications become subjects of public scrutiny.

Of course, the likes of int'Veld have good reasons to seize the present moment to make the European Parliament look appear relevant, in spite of its many shortcomings and its limited role in actual European policymaking.

However, not only is giving more power to the parliament not the answer to the EU's democratic deficit, but also the parliamentarians' current attempt circumscribe the space in which public officials – this time those in the European Commission – can bargain in confidence risks leading to bureaucratic paralysis and ultimately making the EU and its institutions irrelevant.

Author bio

Dalibor Rohac is a senior fellow at the American Enterprise Institute in Washington DC.

Disclaimer

The views expressed in this opinion piece are the author's, not those of EUobserver.

Von der Leyen slammed for not revealing Pfizer CEO texts

The European ombudsman has criticised the European Commission for its handling of a request for public access of text messages that were exchanged between president Ursula von der Leyen and Pfizer CEO Albert Bourla.

Don't Look Up - but for vaccines

Netflix's satirical disaster movie, Don't Look Up, is primarily a warning about our failure to act on climate change but it's plot will seem strangely familiar to anyone who has observed the EU approach to Covid-19 vaccines, particularly patent-waivers.

Podcast

Transparency, Interrupted

The European Union adopted its access regulation at the turn of this century. But as work went digital, the rules have failed to keep pace. A lot still goes unrecorded or unregistered, and cannot be accessed easily, if at all.

EU Ombudsman: Missing texts with Pfizer CEO are 'wake-up call'

The EU Ombudsman said missing texts between European Commission president Ursula von der Leyen and the boss of Pfizer are a "wake-up call" for all institutions about how they should handle work-related instant messages in the digital era.

Europe is giving more aid to Ukraine than you think

'Europeans need to pull their weight in Ukraine. They should pony up more funds.' Such has been the chorus since the start of the war. The problem is the argument isn't borne out by the facts, at least not anymore.

More money, more problems in EU answer to US green subsidies

Industrial energy-intense sectors, outside Germany and France, will not move to the US. They will go bust, as they cannot compete in a fragmented single market. So to save industry in two member states, we will kill the rest?

Latest News

  1. MEPs launch anonymous drop-box for shady lobbying secrets
  2. Hawkish ECB rate-rise 'puts energy transition at risk'
  3. MEPs push for greater powers for workers' councils
  4. How Pavel won big as new Czech president — and why it matters
  5. French official to take on Islamophobia in EU
  6. EU green industry plan could spark 'dangerous subsidy race'
  7. Wolves should be defended, EU ministers urge
  8. EU Commission wants drones for Bulgaria on Turkey border

Stakeholders' Highlights

  1. Party of the European LeftJOB ALERT - Seeking a Communications Manager (FT) for our Brussels office!
  2. European Parliamentary Forum for Sexual & Reproductive Rights (EPF)Launch of the EPF Contraception Policy Atlas Europe 2023. 8th February. Register now.
  3. Europan Patent OfficeHydrogen patents for a clean energy future: A global trend analysis of innovation along hydrogen value chains
  4. Forum EuropeConnecting the World from the Skies calls for global cooperation in NTN rollout
  5. EFBWWCouncil issues disappointing position ignoring the threats posed by asbestos
  6. Nordic Council of MinistersLarge Nordic youth delegation at COP15 biodiversity summit in Montreal

Stakeholders' Highlights

  1. Nordic Council of MinistersCOP27: Food systems transformation for climate action
  2. Nordic Council of MinistersThe Nordic Region and the African Union urge the COP27 to talk about gender equality
  3. Friedrich Naumann Foundation European DialogueGender x Geopolitics: Shaping an Inclusive Foreign Security Policy for Europe
  4. Obama FoundationThe Obama Foundation Opens Applications for its Leaders Program in Europe
  5. EFBWW – EFBH – FETBBA lot more needs to be done to better protect construction workers from asbestos
  6. European Committee of the RegionsRe-Watch EURegions Week 2022

Join EUobserver

Support quality EU news

Join us